A phase I dose escalation study of Upamostat in Chinese patients with solid tumour

Trial Profile

A phase I dose escalation study of Upamostat in Chinese patients with solid tumour

Planning
Phase of Trial: Phase I

Latest Information Update: 17 Jan 2016

At a glance

  • Drugs Upamostat (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 17 Jan 2016 New trial record
    • 13 Jan 2016 According to a Wiles AG media release, the company announced that Link Health Co. submitted an IND application to the CFDA (China Food and Drug Administration) of Mesupron (Upamostat) for the treatment of solid tumour.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top